Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYSCRAPER-07 in unresectable esophageal squamous cell carcinoma after definitive chemoradiotherapy
2022-502052-30-00Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing tiragolumab + atezolizumab, placebo + atezolizumab and double placebo (3 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jul 2024; status: completed.
02
Drugs
tiragolumabatezolizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2022-502052-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502052-30-00.